US20180271118A1 - Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health - Google Patents
Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health Download PDFInfo
- Publication number
- US20180271118A1 US20180271118A1 US15/542,091 US201615542091A US2018271118A1 US 20180271118 A1 US20180271118 A1 US 20180271118A1 US 201615542091 A US201615542091 A US 201615542091A US 2018271118 A1 US2018271118 A1 US 2018271118A1
- Authority
- US
- United States
- Prior art keywords
- ovarian
- vitamin
- feed
- combination
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/807—Poultry or ruminant feed
Definitions
- This invention relates to the combination of 25-hydroxyvitamin D (“25-OH D3” and/or “25-OH D2”) and antioxidants/anti-inflammatories (ascorbic acid, Vitamin E and canthaxanthin) for use in poultry feed to benefit ovarian health.
- 25-hydroxyvitamin D (“25-OH D3” and/or “25-OH D2”)
- antioxidants/anti-inflammatories ascorbic acid, Vitamin E and canthaxanthin
- This combination of nutritional supplements protects poultry against various adverse effects in the ovaries which are associated with hyperphagia such as increased ovarian degeneration and increased tumor formation. It also relates to feed and feed premixes containing the combination of 25-hydroxyvitamin D and the antioxidants/anti-inflammatories for use in protecting ovarian health.
- LHRH luteinizing hormone releasing hormone
- FSH follicle stimulating hormone
- the ovary of an immature pullet has only small undifferentiated follicles invisible to the naked eye. These follicles, upon sexual maturity, increase in size to form an array of small follicles as well as a hierarchy of large follicles varying in size.
- the small follicles produce estrogen after hypothalamic maturation.
- the large yellow follicles are usually defined as being greater than 1 cm in diameter, and their numbers are directly influenced by lighting program, plane of nutrition and breeder age. Progesterone released from the largest follicle triggers the ovulation process. Mature follicles are capable of producing progesterone only a few hours prior to ovulation.
- the liver is a key organ in egg production as it is the site of lipogenesis, leading to formation of fatty acids and subsequently triglycerides that contribute to egg yolk formation, which is in turn driven by estrogen.
- the skeletal system is intimately associated with egg production for its role in mobilizing, storing and releasing calcium under the influence of estrogen.
- Hyperphagia and therefore adiposity occurs in broiler breeder females as a consequence of genetic selection for rapid growth in broiler chickens.
- Overfeeding-induced ovarian dysfunction and reproductive inefficiency as well as metabolic disorders like ascites, sudden death syndrome and fatty liver in broiler breeder females is a consequence of lipotoxicity development as result of fuel overloading the biological system. Therefore, the challenge of managing modern female broiler breeder strains is the inability of these hens to adequately self-regulate feed intake during growth and development to achieve an optimal body weight and composition to support efficient egg and chick production.
- broiler breeder females are subject to a high degree of restricted feeding regimen.
- the primary mechanism in which feed restriction benefits reproductive efficiency in broiler breeder females is the control of follicle development or rather limiting the formation of excessive numbers of ovarian yellow follicles arranged in multiple hierarchies.
- Broiler breeder females overfed during reproductive development not only produce excess large yellow ovarian follicles but also generate a greater number of atretic yellow follicles and commonly display erratic oviposition and defective egg syndrome (EODES) that include several reproductive problems such as follicular atresia, the production of soft-shelled or membranous eggs, double-yolked eggs, egg yolk peritonitis (presence of egg yolk in the abdominal cavity), multiple egg days and oviposition not occurring in sequence, resulting in increased production of unsettable eggs.
- EODES erratic oviposition and defective egg syndrome
- Hy•D® (registered trademark for 25-OH-D3; available from DSM Nutritional Products, Switzerland has been used to promote bone health in poultry.
- WO2010/057811 DSM IP ASSETS, BV
- MAXICHICK The combination of 25-OH D3 and canthaxanthin has also been used in poultry.
- WO2010/057811 DSM IP ASSETS, BV
- the combination is commercially available under the trademark MAXICHICK.
- MAXICHICK There is no mention in the patent publication of the inclusion of ascorbic acid, the use of high vitamin E levels, nor the uses to benefit ovarian health.
- Vitamin C is often not included as a supplement in poultry diets, as chicken, under normal rearing conditions can produce sufficient Vitamin C. However, it has been used in some specific conditions, such as in heat stress situations.
- Vitamin E is generally added to poultry feed. Recommended doses for broilers tends to range from about 50-100 IU/kg feed, depending on the age of the animal.
- WO14/202433 (DSM IP ASSETS B.V) teaches the combination of canthaxanthin and 25-OH D3 to improve internal egg quality, i.e. enhancing the strength of vitelline membrane that envelopes the yolk. There is no teaching to add ascorbic acid to the combination, nor for its use in ameliorating the adverse effects of hyperphagia-related obesity.
- WO14/191153 (DSM IP ASSETS B.V) teaches the combination of canthaxanthin and at least one of Vitamin C, Vitamin E, selenium, and optionally at least one of thymol, eugenol, vanillin and gamma-terpinene can improve immune statues, bone health, skeletal development and growth and feed conversion, particularly when flocks are subject to stress associated with vaccination.
- antioxidants of this invention comprise the combination of ascorbic acid, vitamin E and canthaxanthin, although it has also been found, in accordance with this invention that they antioxidants also possess anti-inflammatory activities and thus are referred to as “antioxidant/anti-inflammatories”.
- one aspect of this invention is the combination of 25-OH D3, canthaxanthin, vitamin E and ascorbic acid to benefit ovarian health.
- Another embodiment is the combination of 25-OHD2, canthaxanthin, Vitamin E and ascorbic acid to benefit ovarian health.
- Another embodiment is the combination of 25-OHD3, 25-OHD2, canthaxanthin, Vitamin E and ascorbic acid to benefit ovarian health.
- 25-OH D2 and 25-OH D3 may act in a similar fashion after administration, it is envisioned that either may be used separately in combination with antioxidants/anti-inflammatories/anti-inflammatories, or a mixture of both 25-OH D3 and 25-OH D2 may be used in combination with antioxidants/anti-inflammatories/anti-inflammatories. If used together, the ratio of 25-OH D3: 25-OH D3 is not a critical part of the invention.
- Another aspect of this invention is the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid, which optionally further comprises at least one further bio-active ingredient selected from the group consisting of:
- a further aspect is the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid which optionally further comprises at least one further bio-active ingredient selected from the group consisting of Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pantothenic Acid, Folic Acid, Biotin, Zinc, Copper, Manganese, Selenium, and combinations thereof to benefit ovarian health.
- the 25-OH D is 25-OH D3.
- the further bio-active ingredient includes biotin.
- the further bio-active ingredient includes Vitamin D and biotin.
- the further bio-active ingredient includes all the aforementioned optionally bio-active ingredients.
- Another aspect of this invention is a poultry feed which benefits ovarian health comprising the combination of 25-OH D2 or 25-OH D3 or mixtures thereof, ascorbic acid, Vitamin E and canthaxanthin.
- poultry feed which benefits ovarian health comprising the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid, which optionally further comprises at least one further bio-active ingredient selected from the group consisting of: Vitamin D, Vitamin B2, Vitamin B6, Niacin, Zinc, Copper, Manganese, Selenium and combinations thereof.
- the 25-OH D is 25-OH D3.
- the further bio-active ingredients include at least Vitamin D and Selenium. In some cases, all the further bio-active ingredients are added.
- Another embodiment is poultry feed benefiting ovarian health comprising the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid, which optionally further comprises at least one further bio-active ingredient selected from the group consisting of: Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pantothenic Acid, Folic Acid, Biotin, Zinc, Copper, Manganese, Selenium and combinations thereof.
- the further bio-active ingredient includes biotin.
- the 25-OH D is 25-OH D3.
- the further bio-active ingredient includes Vitamin D and biotin.
- the further bio-active ingredient includes all the aforementioned optionally bio-active ingredients.
- premixes for poultry feed that benefits ovarian health which comprise the combination of 25-OH D, vitamin E, ascorbic acid and canthaxanthin.
- the 25-OH D is 25-OH D3.
- the feed and premix also comprises at least one further bio-active ingredient selected from the group consisting of:
- premixes for poultry feed which benefits ovarian health which further comprise at least one further bio-active ingredient selected from the group consisting of: Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pantothenic Acid, Folic Acid, Biotin, Zinc, Copper, Manganese, Selenium and combinations thereof.
- the further bio-active ingredient includes biotin.
- the further bio-active ingredient includes Vitamin D and biotin.
- the further bio-active ingredient includes all the aforementioned optionally bio-active ingredients.
- the 25-OH D and antioxidants/anti-inflammatories of this invention are all used in poultry which are fed a complete diet, so they are not vitamin/mineral deficient.
- the 25-OH D and antioxidant/combination of this invention is not acting to remedy a vitamin or other nutrient deficiency. It can be considered a supra-physiological dosage.
- the animals When using the poultry feed of this invention, the animals may be fed ad libitum and the ill effects on ovarian health normally experienced will be experienced to a lesser degree or not at all. This results in easier flock management, and eliminates the problems encountered where the flock is fed a restricted diet, but certain individual birds still exhibit hyperphagia, and may show aggressive behaviors towards other birds.
- FIGS. 1-3 show pictures taken during the necropsy of broiler hens in response to ad libitum feed intake in combination with vitamin D and antioxidant inclusion. Hens were necropsied after 10 weeks of the feeding trial.
- FIG. 1 top left shows an abnormal ventricle, as seen in the untreated group, as compared to a normal ventricle.
- the middle left and right show transudate within the pericardium.
- the lower row shows normal pericardia.
- FIG. 2 shows ascites which were found in the abdominal cavity (top left) versus a normal abdominal cavity.
- the lower row shows tumor-like morphology in the ovary (left), degenerate morphology (center) and normal morphology (right).
- FIG. 3 shows abnormal livers (cirrhosis, left) (fatty liver, center) and a normal liver (right).
- 25-OH D refers to any form of 25-hydroxyvitamin D (i.e. either 25-OH D2 or 25-OH D3, or mixes thereof).
- 25-OH D3 specifically refers to 25-hydroxyvitamin D3;
- 25-OH D2 specifically refers to 25-hydroxyvitamin D2.
- Pigtry means any domesticated fowl, including chickens (including broiler, layers and breeding hens), ducks, geese, turkeys, quail, and ostriches.
- “Hyperphagia” is excessive eating; the animal does not voluntarily limit its feeding.
- “Ovarian health” in this invention relies on the following distinct measurable parameters: the amount of ovarian degeneration and ovarian tumors. Benefiting/improving ovarian health thus means that at least one of the following conditions is present upon feeding the combination of this invention:
- feed comprising 25-OH D3, vitamin E, canthaxanthin and ascorbic acid
- canthaxanthin and ascorbic acid can specifically contribute to ovarian health.
- Broiler breeder females overfed during reproductive development not only produce excess large yellow ovarian follicles but also generate a greater number of atretic yellow follicles and commonly display erratic oviposition and defective egg syndrome (EODES) that include several reproductive problems such as follicular atresia, the production of soft-shelled or membranous eggs, double-yolked eggs, egg yolk peritonitis (presence of egg yolk in the abdominal cavity), multiple egg days and oviposition not occurring in sequence, resulting in increased production of unsettable eggs.
- Use of the feed/premix of this invention can lessen, reduce, ameliorate or eliminate each of these conditions.
- one aspect of this invention is a combination comprising 25-Hydroxy vitamin D, ascorbic acid, Vitamin E and canthaxanthin for use in a poultry feed promoting ovarian health, wherein ovarian health is indicated by at least one indicia of ovarian health selected from the group consisting of:
- feed comprising 25-OH D3, vitamin E, canthaxanthin and ascorbic acid can be used in an ad libitum feeding scheme, and will result in poultry which exhibit at least one of these characteristics:
- the amount of 25-OH D3 can range from 15-200 ⁇ g/kg feed.
- the amount of 25-OH D3 is from 35-150 ⁇ g/kg feed.
- 35 ⁇ g per kg 25-OH D3/feed is preferred; for food with a medium dose of the combination, 69 ⁇ g per kg feed is preferred; and for food with a high dose of 150 ⁇ g feed is preferred.
- the amount of Vitamin E can range from 40-400 mg/kg feed. Preferably the amount is 80-300 mg/kg feed. For feed with a low dose of the combination of the invention, 80 mg/kg Vitamin E is preferred. For feed with a medium dose, 150 mg Vitamin E is preferred; for feed with a high dose, 300 mg/kg Vitamin E is preferred.
- the amount of canthaxanthin can range from 1-15 mg/kg feed. Preferably the amount is 3-12 mg/kg feed. For feed with a low dose of the combination of the invention, 3 mg/kg canthaxanthin is preferred. For feed with a medium dose, 6 mg canthaxanthin is preferred; for feed with a high dose, 12 mg/kg canthaxanthin is preferred.
- the amount of ascorbic acid can range from 40-400 mg/kg feed. Preferably the amount is 100-300 mg feed. For feed with a low dose of the combination of the invention, 100 mg/kg ascorbic acid is preferred. For feed with a medium dose, 150 mg ascorbic acid is preferred; for feed with a high dose, 300 mg/kg ascorbic acid is preferred.
- At least one of the additional ingredients may be added.
- at least one, and more preferably more than one of the following ingredients are added.
- all the following ingredients are added:
- a total of thirty 45-week-old broiler breeder hens (ROSS 308) were obtained from a commercial flock for the study.
- a basal broiler breeder laying diet was formulated as shown in Table 1.
- the calculated nutrient composition is shown in Table 2.
- composition of the basal broiler breeder laying diets Composition %, w/w Corn 66.9 Soybean meal 22.2 Oil fat 1.67 Ca Carbonate (ground 6.36 oyster shell) Dicalcium phosphate 1.8 Choline-Cl (70%) 0.1 Mineral Premix 1 0.1 Copper sulfate 0.05 Vitamin Premix 2 0.1 1 Mineral premix provided (per kg of diet for treatment groups 1, 2 and 3): Cu 18 mg; I 1.1 mg; Fe 80 mg; Mn 150 mg; Zn 125 mg; and Se 0.25 mg. 2 Refer to Table 2 for further detail.
- Diet was supplemented with or without 25-OH D3 at 69 mcg/kg diet in combination with antioxidants/anti-inflammatories (ascorbic acid, canthaxanthin) and enriched levels of selected vitamins. Hens were randomly allocated to 3 treatment groups according to feeding regimen (restricted and ad libitum) as follows:
- Basal diet restricted feeding (140 g/day) 2. Basal diet—ad libitum feeding 3. Basal diet—ad libitum feeding+25-OH-D3 at 69 mcg/kg diet+antioxidants/anti-inflammatories
- estradiol secretion of estradiol is the hallmark of successful ovulatory follicles. In addition to its role in triggering the preovulatory surge of gonadotropins, estradiol is an important intra-ovarian growth, differentiation, and survival factor. Inclusion of 25-hydroxy D3 and antioxidants/anti-inflammatories reduced mortality and incidence of ovarian degeneration and ovarian-tumor-like morphology, increased egg production and sustained plasma estradiol levels in birds under ad libitum feed intake.
- Supplemental 25-hydroxy D3 and antioxidants/anti-inflammatories ameliorated deleterious effects associated with overfeeding of broiler breeder females by lowering mortality rate and improving ovary function and therefore reproductive performance of overfed broiler breeder hens.
Abstract
Description
- This invention relates to the combination of 25-hydroxyvitamin D (“25-OH D3” and/or “25-OH D2”) and antioxidants/anti-inflammatories (ascorbic acid, Vitamin E and canthaxanthin) for use in poultry feed to benefit ovarian health. This combination of nutritional supplements protects poultry against various adverse effects in the ovaries which are associated with hyperphagia such as increased ovarian degeneration and increased tumor formation. It also relates to feed and feed premixes containing the combination of 25-hydroxyvitamin D and the antioxidants/anti-inflammatories for use in protecting ovarian health.
- Reproductive efficiency and the incidence of pathogenic disorders are directly influenced by the extent of ovary development and nutrition in poultry. For example, the finely tuned reproductive system of the broiler breeder female requires ovary, oviduct, brain, liver and skeletal system to communicate among themselves under the influence of lighting in the production of hatching eggs. The hypothalamus, located within the brain, is directly stimulated by light energy at photostimulation. The mature (reproductively functional) hypothalamus then secretes luteinizing hormone releasing hormone (LHRH), which acts on anterior pituitary to stimulate the production of luteinizing hormone (LH) and follicle stimulating hormone (FSH). Both LH and FSH target the ovary and stimulate ovarian hormone production and early follicle development, respectively.
- The ovary of an immature pullet has only small undifferentiated follicles invisible to the naked eye. These follicles, upon sexual maturity, increase in size to form an array of small follicles as well as a hierarchy of large follicles varying in size. The small follicles produce estrogen after hypothalamic maturation. The large yellow follicles are usually defined as being greater than 1 cm in diameter, and their numbers are directly influenced by lighting program, plane of nutrition and breeder age. Progesterone released from the largest follicle triggers the ovulation process. Mature follicles are capable of producing progesterone only a few hours prior to ovulation. The liver is a key organ in egg production as it is the site of lipogenesis, leading to formation of fatty acids and subsequently triglycerides that contribute to egg yolk formation, which is in turn driven by estrogen. The skeletal system is intimately associated with egg production for its role in mobilizing, storing and releasing calcium under the influence of estrogen.
- Hyperphagia and therefore adiposity occurs in broiler breeder females as a consequence of genetic selection for rapid growth in broiler chickens. Overfeeding-induced ovarian dysfunction and reproductive inefficiency as well as metabolic disorders like ascites, sudden death syndrome and fatty liver in broiler breeder females is a consequence of lipotoxicity development as result of fuel overloading the biological system. Therefore, the challenge of managing modern female broiler breeder strains is the inability of these hens to adequately self-regulate feed intake during growth and development to achieve an optimal body weight and composition to support efficient egg and chick production. As such, broiler breeder females are subject to a high degree of restricted feeding regimen. The primary mechanism in which feed restriction benefits reproductive efficiency in broiler breeder females is the control of follicle development or rather limiting the formation of excessive numbers of ovarian yellow follicles arranged in multiple hierarchies.
- Broiler breeder females overfed during reproductive development not only produce excess large yellow ovarian follicles but also generate a greater number of atretic yellow follicles and commonly display erratic oviposition and defective egg syndrome (EODES) that include several reproductive problems such as follicular atresia, the production of soft-shelled or membranous eggs, double-yolked eggs, egg yolk peritonitis (presence of egg yolk in the abdominal cavity), multiple egg days and oviposition not occurring in sequence, resulting in increased production of unsettable eggs.
- Controlled studies reported that voluntary feeding (i.e., broiler breeder hens to satiation) resulted in poor egg production, high rate of mortality and abnormal ovarian structure (mainly overt hierarchical follicle atresia). Lipotoxicity results in impaired ovarian dysfunctions, including follicle atresia, ovarian regression, and a decline of circulating estradiol levels in feed-satiated hens.
- Despite restricted feeding regimen strictly implemented in commercial broiler breeder flocks, it is still very easy to overfeed breeder hens due to their intrinsic hyperphagia. Furthermore, breeder farm managers are confronted as to when and how to feed before and during the start of egg production as well as towards, during and after peak production. The basic fundamental question to ask what and how management and nutritional tools breeder farm managers can apply and implement to ameliorate the adverse and deleterious effects of reproductive efficiency associated with obesity in overweight hens.
- Hy•D® (registered trademark for 25-OH-D3; available from DSM Nutritional Products, Switzerland has been used to promote bone health in poultry.
- The combination of 25-OH D3 and canthaxanthin has also been used in poultry. WO2010/057811 (DSM IP ASSETS, BV) describes the combination for use in improving hatchability, fertility, and lower embryo mortality in poultry. The combination is commercially available under the trademark MAXICHICK. There is no mention in the patent publication of the inclusion of ascorbic acid, the use of high vitamin E levels, nor the uses to benefit ovarian health.
- Vitamin C (ascorbic acid) is often not included as a supplement in poultry diets, as chicken, under normal rearing conditions can produce sufficient Vitamin C. However, it has been used in some specific conditions, such as in heat stress situations.
- Vitamin E is generally added to poultry feed. Recommended doses for broilers tends to range from about 50-100 IU/kg feed, depending on the age of the animal.
- WO14/202433 (DSM IP ASSETS B.V) teaches the combination of canthaxanthin and 25-OH D3 to improve internal egg quality, i.e. enhancing the strength of vitelline membrane that envelopes the yolk. There is no teaching to add ascorbic acid to the combination, nor for its use in ameliorating the adverse effects of hyperphagia-related obesity.
- WO14/191153 (DSM IP ASSETS B.V) teaches the combination of canthaxanthin and at least one of Vitamin C, Vitamin E, selenium, and optionally at least one of thymol, eugenol, vanillin and gamma-terpinene can improve immune statues, bone health, skeletal development and growth and feed conversion, particularly when flocks are subject to stress associated with vaccination.
- Thus there is a need to reduce or ameliorate the metabolic and hormonal dysregulations as a result of hyperphagia in broiler breeder hens which induce affect ovarian health.
- It has been found, accordance with this invention that the combination of 25-hydroxyvitamin D (25-OH D3 and/or 25-OH D2) and antioxidants/anti-inflammatories ameliorates adverse ovarian health observed when poultry is fed ad libitum or experiences hyperphagia-related obesity. The antioxidants of this invention comprise the combination of ascorbic acid, vitamin E and canthaxanthin, although it has also been found, in accordance with this invention that they antioxidants also possess anti-inflammatory activities and thus are referred to as “antioxidant/anti-inflammatories”.
- Thus one aspect of this invention is the combination of 25-OH D3, canthaxanthin, vitamin E and ascorbic acid to benefit ovarian health. Another embodiment is the combination of 25-OHD2, canthaxanthin, Vitamin E and ascorbic acid to benefit ovarian health. Another embodiment is the combination of 25-OHD3, 25-OHD2, canthaxanthin, Vitamin E and ascorbic acid to benefit ovarian health.
- As 25-OH D2 and 25-OH D3 may act in a similar fashion after administration, it is envisioned that either may be used separately in combination with antioxidants/anti-inflammatories/anti-inflammatories, or a mixture of both 25-OH D3 and 25-OH D2 may be used in combination with antioxidants/anti-inflammatories/anti-inflammatories. If used together, the ratio of 25-OH D3: 25-OH D3 is not a critical part of the invention.
- Another aspect of this invention is the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid, which optionally further comprises at least one further bio-active ingredient selected from the group consisting of:
-
- Vitamin D, Vitamin B2, Vitamin B6, Niacin, Zinc, Copper, Manganese, and Selenium. Preferably the 25-OH D is 25-OH D3 to benefit ovarian health. Preferably at least Vitamin D is a further bio-active ingredient. Sometimes the further bio-active ingredients include at least Vitamin D and Selenium. In some cases, all the further bio-active ingredients are added.
- A further aspect is the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid which optionally further comprises at least one further bio-active ingredient selected from the group consisting of Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pantothenic Acid, Folic Acid, Biotin, Zinc, Copper, Manganese, Selenium, and combinations thereof to benefit ovarian health. Preferably the 25-OH D is 25-OH D3. Sometimes, the further bio-active ingredient includes biotin. Sometimes the further bio-active ingredient includes Vitamin D and biotin. Sometimes the further bio-active ingredient includes all the aforementioned optionally bio-active ingredients.
- Another aspect of this invention is a poultry feed which benefits ovarian health comprising the combination of 25-OH D2 or 25-OH D3 or mixtures thereof, ascorbic acid, Vitamin E and canthaxanthin.
- Yet another embodiment is poultry feed which benefits ovarian health comprising the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid, which optionally further comprises at least one further bio-active ingredient selected from the group consisting of: Vitamin D, Vitamin B2, Vitamin B6, Niacin, Zinc, Copper, Manganese, Selenium and combinations thereof. Preferably the 25-OH D is 25-OH D3. Sometimes the further bio-active ingredients include at least Vitamin D and Selenium. In some cases, all the further bio-active ingredients are added.
- Another embodiment is poultry feed benefiting ovarian health comprising the combination of 25-OH D, canthaxanthin, vitamin E and ascorbic acid, which optionally further comprises at least one further bio-active ingredient selected from the group consisting of: Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pantothenic Acid, Folic Acid, Biotin, Zinc, Copper, Manganese, Selenium and combinations thereof. Sometimes, the further bio-active ingredient includes biotin. Preferably the 25-OH D is 25-OH D3. Sometimes the further bio-active ingredient includes Vitamin D and biotin. Sometimes the further bio-active ingredient includes all the aforementioned optionally bio-active ingredients.
- Another aspect of this invention are premixes for poultry feed that benefits ovarian health which comprise the combination of 25-OH D, vitamin E, ascorbic acid and canthaxanthin. Preferably, the 25-OH D is 25-OH D3. In some embodiments the feed and premix also comprises at least one further bio-active ingredient selected from the group consisting of:
-
- Vitamin D, Vitamin B2, Vitamin B6, Niacin, Zinc, Copper, Manganese, Selenium and combinations thereof. Sometimes the further bio-active ingredients include at least Vitamin D and Selenium. In some cases, all the further bio-active ingredients are added.
- Another aspect of this invention are premixes for poultry feed which benefits ovarian health which further comprise at least one further bio-active ingredient selected from the group consisting of: Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pantothenic Acid, Folic Acid, Biotin, Zinc, Copper, Manganese, Selenium and combinations thereof. Sometimes, the further bio-active ingredient includes biotin. Sometimes the further bio-active ingredient includes Vitamin D and biotin. Sometimes the further bio-active ingredient includes all the aforementioned optionally bio-active ingredients.
- In another aspect, the 25-OH D and antioxidants/anti-inflammatories of this invention are all used in poultry which are fed a complete diet, so they are not vitamin/mineral deficient. Thus, the 25-OH D and antioxidant/combination of this invention is not acting to remedy a vitamin or other nutrient deficiency. It can be considered a supra-physiological dosage.
- When using the poultry feed of this invention, the animals may be fed ad libitum and the ill effects on ovarian health normally experienced will be experienced to a lesser degree or not at all. This results in easier flock management, and eliminates the problems encountered where the flock is fed a restricted diet, but certain individual birds still exhibit hyperphagia, and may show aggressive behaviors towards other birds.
-
FIGS. 1-3 show pictures taken during the necropsy of broiler hens in response to ad libitum feed intake in combination with vitamin D and antioxidant inclusion. Hens were necropsied after 10 weeks of the feeding trial. -
FIG. 1 , top left shows an abnormal ventricle, as seen in the untreated group, as compared to a normal ventricle. The middle left and right show transudate within the pericardium. The lower row shows normal pericardia. -
FIG. 2 shows ascites which were found in the abdominal cavity (top left) versus a normal abdominal cavity. The lower row shows tumor-like morphology in the ovary (left), degenerate morphology (center) and normal morphology (right). -
FIG. 3 shows abnormal livers (cirrhosis, left) (fatty liver, center) and a normal liver (right). - As used throughout this specification and claims, the following definitions apply: “25-OH D” refers to any form of 25-hydroxyvitamin D (i.e. either 25-OH D2 or 25-OH D3, or mixes thereof). 25-OH D3 specifically refers to 25-hydroxyvitamin D3; 25-OH D2 specifically refers to 25-hydroxyvitamin D2.
- “Poultry” means any domesticated fowl, including chickens (including broiler, layers and breeding hens), ducks, geese, turkeys, quail, and ostriches.
- “Hyperphagia” is excessive eating; the animal does not voluntarily limit its feeding.
- “Ovarian health” in this invention relies on the following distinct measurable parameters: the amount of ovarian degeneration and ovarian tumors. Benefiting/improving ovarian health thus means that at least one of the following conditions is present upon feeding the combination of this invention:
-
- a) ovarian degeneration is lessened, occurs at a later onset, or does not occur
- b) ovarian tumors are reduced in number, reduced in size, reduced in both size and number, occur at a later onset, or do not occur.
- “Ascorbic Acid” and “Vitamin C” are used interchangeably throughout the specification and claims.
- It has been found in accordance with this invention, that the use of feed comprising 25-OH D3, vitamin E, canthaxanthin and ascorbic acid can specifically contribute to ovarian health. Broiler breeder females overfed during reproductive development not only produce excess large yellow ovarian follicles but also generate a greater number of atretic yellow follicles and commonly display erratic oviposition and defective egg syndrome (EODES) that include several reproductive problems such as follicular atresia, the production of soft-shelled or membranous eggs, double-yolked eggs, egg yolk peritonitis (presence of egg yolk in the abdominal cavity), multiple egg days and oviposition not occurring in sequence, resulting in increased production of unsettable eggs. Use of the feed/premix of this invention can lessen, reduce, ameliorate or eliminate each of these conditions.
- Thus one aspect of this invention is a combination comprising 25-Hydroxy vitamin D, ascorbic acid, Vitamin E and canthaxanthin for use in a poultry feed promoting ovarian health, wherein ovarian health is indicated by at least one indicia of ovarian health selected from the group consisting of:
-
- a) reduced ovarian degeneration, occurrence of ovarian degeneration at a later onset, or no occurrence of ovarian degeneration; and
- b) reduction in the amount of ovarian tumors, reduction in size of ovarian tumors, reduction in both size and number of ovarian tumors, occurrence at a later onset, or no occurrence of ovarian tumors.
- Specifically it has been found that feed comprising 25-OH D3, vitamin E, canthaxanthin and ascorbic acid can be used in an ad libitum feeding scheme, and will result in poultry which exhibit at least one of these characteristics:
-
- a) ovarian degeneration is lessened, occurs at a later onset, or does not occur;
- b) ovarian tumors are reduced in number, reduced in size, reduced in both size and number, occur at a later onset, or do not occur.
- Hens with ovarian degeneration, large follicle atresia or tumors or other abnormal morphology such as internal ovulation, tend to have a lower egg production rate than in their past records. Hens with obesity and related dysregulations such as plasma lipids and ceramide or insulin and leptin level, or tissue cytokine and lipid content tend to have a rapid ovarian degeneration and other abnormalities and thereby a lower egg production rate which can be easily monitored.
- The amount of 25-OH D3 can range from 15-200 μg/kg feed. Preferably, the amount of 25-OH D3 is from 35-150 μg/kg feed. For feed with a low dose of the combination of the invention, 35 μg per kg 25-OH D3/feed is preferred; for food with a medium dose of the combination, 69 μg per kg feed is preferred; and for food with a high dose of 150 μg feed is preferred.
- The amount of Vitamin E can range from 40-400 mg/kg feed. Preferably the amount is 80-300 mg/kg feed. For feed with a low dose of the combination of the invention, 80 mg/kg Vitamin E is preferred. For feed with a medium dose, 150 mg Vitamin E is preferred; for feed with a high dose, 300 mg/kg Vitamin E is preferred.
- The amount of canthaxanthin can range from 1-15 mg/kg feed. Preferably the amount is 3-12 mg/kg feed. For feed with a low dose of the combination of the invention, 3 mg/kg canthaxanthin is preferred. For feed with a medium dose, 6 mg canthaxanthin is preferred; for feed with a high dose, 12 mg/kg canthaxanthin is preferred.
- The amount of ascorbic acid can range from 40-400 mg/kg feed. Preferably the amount is 100-300 mg feed. For feed with a low dose of the combination of the invention, 100 mg/kg ascorbic acid is preferred. For feed with a medium dose, 150 mg ascorbic acid is preferred; for feed with a high dose, 300 mg/kg ascorbic acid is preferred.
- Thus specific preferred feeds of this invention comprise the following dosages (all amounts are per kg/feed):
-
-
- 25-OH D3: 15-200 μg,
- Vitamin E: 40-400 mg,
- Canthaxanthin: 1-15 mg; and
- Ascorbic acid: 40-400 mg.
-
-
- 25-OH D3: 35-150 μg,
- Vitamin E: 80-300 mg,
- Canthaxanthin: 3-12 mg, and
- Ascorbic acid: 80-300 mg
Preferred Feed #3: (Low dose feed) This feed is preferred for mildly obese poultry. - 25-OH D3: 35 g
- Vitamin E: 80 mg
- Canthaxanthin: 3 mg
- Ascorbic acid: 80 mg.
Preferred Feed #4 (medium dose feed) This feed is preferred for moderately to severely obese poultry: - 25-OH D3: 69 g
- Vitamin E: 150 mg
- Canthaxanthin: 6 mg
- Ascorbic acid: 150 mg.
Preferred Feed #5 (high dose feed) This feed is preferred for severely obese poultry: - 25-OH D3: 150 g
- Vitamin E: 300 mg
- Canthaxanthin: 12 mg
- Ascorbic acid: 300 mg.
- To each of the feeds listed above, at least one of the additional ingredients may be added. Preferably at least one, and more preferably more than one of the following ingredients are added. In other embodiments, all the following ingredients are added:
-
- Vitamin D3—generally this is present in poultry diets at approximately 2500 IU per kg feed. In accordance with this invention, if desired, the amount of Vitamin D is increased to at least 3000 IU per kg.
- Vitamin B2: this can be added at 3-25 mg per kg; preferably from 6-20 mg/kg. For low dose feed, 6 mg/kg is preferred. For medium dose feed, 14 mg/kg is preferred; and for high dose feed 20 mg/kg is preferred.
- Niacin: this can be added at 25-300 mg per kg feed. Preferably it ranges from 60-200 mg/kg. For low dose feed, 60 mg/kg is preferred. For medium dose feed, 120 mg/kg is preferred; and for high dose feed 200 mg/kg is preferred.
- Pantothenic acid: this can be added at 10-120 mg per kg feed. Preferably it ranges from 15-80 mg/kg.
- For low dose feed, 15 mg/kg is preferred. For medium dose feed, 30 mg/kg is preferred; and for high dose feed 80 mg/kg is preferred.
- Folic acid: this can be added at 1-8 mg per kg feed. Preferably it ranges from 2-6 mg/kg. For low dose feed, 2 mg/kg is preferred. For medium dose feed, 4 mg/kg is preferred; and for high dose feed 6 mg/kg is preferred.
- Biotin: this can be added at 0.05-1.0 mg/kg feed. Preferably it ranges from 0.2-0.8 mg/kg. For low dose feed, 0.2 mg/kg is preferred. For medium dose feed, 0.4 mg/kg is preferred; and for high dose feed 0.8 mg/kg is preferred.
- Zinc: this can be added at 50-300 mg/kg feed. Preferably it ranges from 70-250 mg/kg. For low dose feed, 70 mg/kg is preferred. For medium dose feed, 125 mg/kg is preferred; and for high dose feed 250 mg/kg is preferred.
- Copper: this can be added at 5-50 mg/kg feed. Preferably it ranges from 10-30 mg/kg. For low dose feed, 10 mg/kg is preferred. For medium dose feed, 20 mg/kg is preferred; and for high dose feed 30 mg/kg is preferred.
- Manganese: this can be added at 50-300 mg/feed. Preferably it ranges from 80-270 mg/kg. For low dose feed, 80 mg/kg is preferred. For medium dose feed, 150 mg/kg is preferred; and for high dose feed 270 mg/kg is preferred.
- Selenium: this can be added at 0.05-0.6 mg/kg feed. Preferably it ranges from 0.1-0.4 mg/kg. For low dose feed, 0.1 mg/kg is preferred. For medium dose feed, 0.2 mg/kg is preferred; and for high dose feed 0.4 mg/kg is preferred.
- The following non-limiting Examples are presented to better illustrate the invention.
- A total of thirty 45-week-old broiler breeder hens (ROSS 308) were obtained from a commercial flock for the study. A basal broiler breeder laying diet was formulated as shown in Table 1. The calculated nutrient composition is shown in Table 2.
-
TABLE 1 Ingredient composition of the basal broiler breeder laying diets. Composition %, w/w Corn 66.9 Soybean meal 22.2 Oil fat 1.67 Ca Carbonate (ground 6.36 oyster shell) Dicalcium phosphate 1.8 Choline-Cl (70%) 0.1 Mineral Premix1 0.1 Copper sulfate 0.05 Vitamin Premix2 0.1 1Mineral premix provided (per kg of diet for treatment groups 1, 2 and 3): Cu 18 mg; I 1.1 mg; Fe 80 mg; Mn 150 mg; Zn 125 mg; and Se 0.25 mg. 2Refer to Table 2 for further detail. -
TABLE 2 Vitamin premix composition (provided per kg of diet) Treatment 3 Treatments 1 and 2 1 = 3 = ad libitum feeding + 25- restricted feeding OH-D3 + antioxidants/anti- Vitamin 2 = ad libitum feeding A(IU) 10000 12000 D3 (IU) 2500 3000 E (mg) 100 150 K3 (mg) 3 5 B1 (mg) 3 3 B2 (mg) 8 14 B6 (mg) 6 8 B12 (mg) 0.03 0.03 Niacin (mg) 60 120 Pantothenic acid 18 30 (mg) Folic acid (mg) 1 4 Biotin (mg) 0.2 0.4 C (ascorbic acid) 0 150 (mg) 25-OH-D3 (mcg) 0 69 Canthaxanthin 0 6 (mg) indicates data missing or illegible when filed -
TABLE 3 Calculated nutrient composition (%) of the basal broiler breeder laying diets. Composition % w/w Crude protein 16 Crude fat 4.2 Calcium 3.1 Sodium 0.16 Total Phosphorus 0.64 Total ME 2910 kcal/kg - Diet was supplemented with or without 25-OH D3 at 69 mcg/kg diet in combination with antioxidants/anti-inflammatories (ascorbic acid, canthaxanthin) and enriched levels of selected vitamins. Hens were randomly allocated to 3 treatment groups according to feeding regimen (restricted and ad libitum) as follows:
- 1. Basal diet—restricted feeding (140 g/day)
2. Basal diet—ad libitum feeding
3. Basal diet—ad libitum feeding+25-OH-D3 at 69 mcg/kg diet+antioxidants/anti-inflammatories - They were individually-housed in wire cages placed in a controlled room with 14 h:10 h light:dark period and at a temperature of 25±3° C. Water was available ad libitum. The experimental period was lasted for 10 weeks. Three weeks after the feeding trial, some birds were used for relevant plasma parameter analyses. At the end of experiment, hens were euthanized and sacrificed for tissue sample collection for further studies.
- Secretion of estradiol is the hallmark of successful ovulatory follicles. In addition to its role in triggering the preovulatory surge of gonadotropins, estradiol is an important intra-ovarian growth, differentiation, and survival factor. Inclusion of 25-hydroxy D3 and antioxidants/anti-inflammatories reduced mortality and incidence of ovarian degeneration and ovarian-tumor-like morphology, increased egg production and sustained plasma estradiol levels in birds under ad libitum feed intake.
- In the group of hens fed the 25-OH D3+antioxidant diet, a lower number of deaths was observed compared to those fed the non-supplemented diet ad libitum. Egg production was significantly higher, and the incident of degenerated ovaries and the incidence of ovarian tumors was lower in the group fed 25-OH D3+anti-oxidants compared to those fed ad-libitum.
- Supplemental 25-hydroxy D3 and antioxidants/anti-inflammatories ameliorated deleterious effects associated with overfeeding of broiler breeder females by lowering mortality rate and improving ovary function and therefore reproductive performance of overfed broiler breeder hens.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/542,091 US20180271118A1 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103769P | 2015-01-15 | 2015-01-15 | |
EP15166937 | 2015-05-08 | ||
EP15166937.1 | 2015-05-08 | ||
PCT/EP2016/050749 WO2016113382A1 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
US15/542,091 US20180271118A1 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/050749 A-371-Of-International WO2016113382A1 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/703,955 Continuation US20220211077A1 (en) | 2015-01-15 | 2022-03-24 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180271118A1 true US20180271118A1 (en) | 2018-09-27 |
Family
ID=53051752
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/542,500 Abandoned US20180264011A1 (en) | 2015-01-15 | 2016-01-15 | Companion animal feed with combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories |
US15/542,187 Active US10517316B2 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for bovine health |
US15/542,509 Abandoned US20180264012A1 (en) | 2015-01-15 | 2016-01-15 | COMBINATION OF 25-HYDROXYVITAMIN D AND ANTI-INFLAMMITORIES FOR SUSTAINED PLASMA 17- ß ESTRADIOL LEVELS |
US15/541,852 Abandoned US20180000124A1 (en) | 2015-01-15 | 2016-01-15 | Poultry feed with combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories |
US15/542,143 Active US10863756B2 (en) | 2015-01-15 | 2016-01-15 | Method of preventing obesity and cardiovascular problems in poultry |
US15/542,091 Abandoned US20180271118A1 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
US17/703,955 Pending US20220211077A1 (en) | 2015-01-15 | 2022-03-24 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/542,500 Abandoned US20180264011A1 (en) | 2015-01-15 | 2016-01-15 | Companion animal feed with combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories |
US15/542,187 Active US10517316B2 (en) | 2015-01-15 | 2016-01-15 | Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for bovine health |
US15/542,509 Abandoned US20180264012A1 (en) | 2015-01-15 | 2016-01-15 | COMBINATION OF 25-HYDROXYVITAMIN D AND ANTI-INFLAMMITORIES FOR SUSTAINED PLASMA 17- ß ESTRADIOL LEVELS |
US15/541,852 Abandoned US20180000124A1 (en) | 2015-01-15 | 2016-01-15 | Poultry feed with combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories |
US15/542,143 Active US10863756B2 (en) | 2015-01-15 | 2016-01-15 | Method of preventing obesity and cardiovascular problems in poultry |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/703,955 Pending US20220211077A1 (en) | 2015-01-15 | 2022-03-24 | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health |
Country Status (9)
Country | Link |
---|---|
US (7) | US20180264011A1 (en) |
EP (6) | EP3244755A1 (en) |
JP (5) | JP6623416B2 (en) |
KR (4) | KR20170103822A (en) |
CN (6) | CN107205442A (en) |
BR (6) | BR112017015209A2 (en) |
CA (1) | CA2973431C (en) |
MX (1) | MX2017009152A (en) |
WO (6) | WO2016113385A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111657229A (en) * | 2020-06-19 | 2020-09-15 | 四川农业大学 | Method for establishing laying hen ovary oxidative stress model |
US11040045B2 (en) | 2015-01-15 | 2021-06-22 | Dsm Ip Assets B.V. | Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for human nutraceuticals |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108935929A (en) * | 2018-06-26 | 2018-12-07 | 辽宁禾丰牧业股份有限公司 | Broiler chicken compound premix and preparation method thereof |
US11723919B2 (en) | 2020-06-12 | 2023-08-15 | Phibro Animal Health Corporation | Composition or combination comprising anionic dietary supplement and 25-hydroxy vitamin D |
CN113598284A (en) * | 2021-08-16 | 2021-11-05 | 广东省农业科学院动物科学研究所 | Application of 25-OH-VD3 in improving ovarian development and egg laying performance |
CN114164169B (en) * | 2021-11-30 | 2022-09-13 | 吉林医药学院 | Application of astaxanthin in promoting development of preantral follicles of mice and preparation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125229A1 (en) * | 2000-03-21 | 2003-07-03 | Rodriguez Gustavo C | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
US20060069151A1 (en) * | 2002-12-06 | 2006-03-30 | Luca Barella | Novel use of lycopene |
US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
WO2010057811A2 (en) * | 2008-11-19 | 2010-05-27 | Dsm Ip Assets B.V. | Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE793052A (en) | 1971-12-20 | 1973-06-20 | Upjohn Co | COMPOSITIONS BASED ON 25-HYDROXYCHOLECALCIFEROL, THEIR PREPARATION AND THEIR USE |
SU1748784A1 (en) * | 1990-12-21 | 1992-07-23 | Московская сельскохозяйственная академия им.К.А.Тимирязева | Method for feeding broilers |
JPH09294544A (en) | 1996-05-02 | 1997-11-18 | Asao Shimanishi | Additive for poultry farming feed |
US6034075A (en) | 1997-03-20 | 2000-03-07 | The Trustees Of Columbia University In The City Of New York | Method of treating polycystic ovarian syndrome |
JPH1135469A (en) | 1997-07-23 | 1999-02-09 | Teijin Ltd | Prophylactic and treating agent for chronic cardiac failure |
US20100098779A1 (en) | 2008-10-22 | 2010-04-22 | Everett Laboratories, Inc. | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
US7560123B2 (en) | 2004-08-12 | 2009-07-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
KR101317976B1 (en) * | 2004-05-18 | 2013-10-14 | 디에스엠 아이피 어셋츠 비.브이. | USE OF β-CRYPTOXANTHIN |
ES2543808T3 (en) * | 2006-02-01 | 2015-08-24 | Nestec S.A. | Nutritional system and methods to increase longevity |
JP2010503387A (en) | 2006-09-14 | 2010-02-04 | ディーエスエム アイピー アセッツ ビー.ブイ. | Feed supplement composition containing one or more vitamin D3 compounds and one or more magnesium salts |
JP2008106023A (en) | 2006-10-27 | 2008-05-08 | Oriza Yuka Kk | Estradiol production promotor |
JP5713520B2 (en) * | 2007-07-25 | 2015-05-07 | 日清丸紅飼料株式会社 | Egg enriched with vitamins, method for producing the egg, and feed used to produce the egg |
WO2009101136A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Treating hyperglycemia with 25-hydroxyvitamin d3 |
WO2009101131A1 (en) | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Treating hypertension with 25-hydroxyvitamin d3 |
GB201013041D0 (en) * | 2010-08-03 | 2010-09-15 | Royal Holloway & New Bedford College | Carotenoids |
ES2589180T3 (en) | 2010-12-23 | 2016-11-10 | Hill's Pet Nutrition, Inc. | Pet food compositions and methods for weight loss and maintenance |
CN102038111B (en) * | 2010-12-27 | 2013-04-24 | 中牧实业股份有限公司 | Compound vitamin for egg-laying chicken |
JP5918784B2 (en) * | 2011-01-07 | 2016-05-18 | ザ ジェネラル ホスピタル コーポレイション | Assays and methods of treatment related to vitamin D deficiency |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
EP3003063A1 (en) * | 2013-05-31 | 2016-04-13 | DSM IP Assets B.V. | Feed supplement and its use |
WO2014202433A1 (en) | 2013-06-18 | 2014-12-24 | Dsm Ip Assets B.V. | Novel use of canthaxanthin |
CN104171391A (en) * | 2014-07-23 | 2014-12-03 | 朱婷婷 | Composite vitamin feed additive for broiler chicken |
-
2016
- 2016-01-15 WO PCT/EP2016/050755 patent/WO2016113385A1/en active Application Filing
- 2016-01-15 BR BR112017015209A patent/BR112017015209A2/en not_active Application Discontinuation
- 2016-01-15 CN CN201680005768.5A patent/CN107205442A/en active Pending
- 2016-01-15 WO PCT/EP2016/050764 patent/WO2016113389A1/en active Application Filing
- 2016-01-15 EP EP16700811.9A patent/EP3244755A1/en active Pending
- 2016-01-15 JP JP2017534242A patent/JP6623416B2/en active Active
- 2016-01-15 CN CN201680005767.0A patent/CN107105712A/en active Pending
- 2016-01-15 EP EP16700637.8A patent/EP3244751A1/en not_active Ceased
- 2016-01-15 BR BR112017015212A patent/BR112017015212A2/en not_active Application Discontinuation
- 2016-01-15 KR KR1020177019461A patent/KR20170103822A/en not_active Application Discontinuation
- 2016-01-15 WO PCT/EP2016/050751 patent/WO2016113383A1/en active Application Filing
- 2016-01-15 EP EP16700638.6A patent/EP3244752A1/en active Pending
- 2016-01-15 JP JP2017534244A patent/JP6623417B2/en active Active
- 2016-01-15 KR KR1020177019460A patent/KR20170103821A/en not_active Application Discontinuation
- 2016-01-15 JP JP2017535025A patent/JP6550651B2/en active Active
- 2016-01-15 US US15/542,500 patent/US20180264011A1/en not_active Abandoned
- 2016-01-15 CN CN201680005770.2A patent/CN107205439A/en active Pending
- 2016-01-15 EP EP16700740.0A patent/EP3244754A1/en active Pending
- 2016-01-15 BR BR112017015210A patent/BR112017015210A2/en not_active Application Discontinuation
- 2016-01-15 BR BR112017015205-3A patent/BR112017015205B1/en active IP Right Grant
- 2016-01-15 WO PCT/EP2016/050749 patent/WO2016113382A1/en active Application Filing
- 2016-01-15 EP EP16700636.0A patent/EP3244750A1/en active Pending
- 2016-01-15 US US15/542,187 patent/US10517316B2/en active Active
- 2016-01-15 WO PCT/EP2016/050753 patent/WO2016113384A1/en active Application Filing
- 2016-01-15 MX MX2017009152A patent/MX2017009152A/en unknown
- 2016-01-15 US US15/542,509 patent/US20180264012A1/en not_active Abandoned
- 2016-01-15 JP JP2017534213A patent/JP6623415B2/en active Active
- 2016-01-15 US US15/541,852 patent/US20180000124A1/en not_active Abandoned
- 2016-01-15 WO PCT/EP2016/050759 patent/WO2016113386A1/en active Application Filing
- 2016-01-15 US US15/542,143 patent/US10863756B2/en active Active
- 2016-01-15 CA CA2973431A patent/CA2973431C/en active Active
- 2016-01-15 JP JP2017534819A patent/JP6623418B2/en active Active
- 2016-01-15 KR KR1020177019493A patent/KR20170103824A/en active IP Right Grant
- 2016-01-15 KR KR1020177019474A patent/KR20170106328A/en not_active Application Discontinuation
- 2016-01-15 CN CN201680005795.2A patent/CN107105717A/en active Pending
- 2016-01-15 EP EP16700738.4A patent/EP3244753A1/en active Pending
- 2016-01-15 CN CN201680005769.XA patent/CN107205441A/en active Pending
- 2016-01-15 CN CN201680005744.XA patent/CN107105711A/en active Pending
- 2016-01-15 BR BR112017015207A patent/BR112017015207A2/en not_active Application Discontinuation
- 2016-01-15 BR BR112017015211-8A patent/BR112017015211B1/en active IP Right Grant
- 2016-01-15 US US15/542,091 patent/US20180271118A1/en not_active Abandoned
-
2022
- 2022-03-24 US US17/703,955 patent/US20220211077A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125229A1 (en) * | 2000-03-21 | 2003-07-03 | Rodriguez Gustavo C | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
US20060069151A1 (en) * | 2002-12-06 | 2006-03-30 | Luca Barella | Novel use of lycopene |
WO2010057811A2 (en) * | 2008-11-19 | 2010-05-27 | Dsm Ip Assets B.V. | Use of canthaxanthin and/or 25-oh d3 for improved hatchability in poultry |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11040045B2 (en) | 2015-01-15 | 2021-06-22 | Dsm Ip Assets B.V. | Combination of 25-hydroxyvitamin D and antioxidants/anti-inflammatories for human nutraceuticals |
CN111657229A (en) * | 2020-06-19 | 2020-09-15 | 四川农业大学 | Method for establishing laying hen ovary oxidative stress model |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220211077A1 (en) | Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for poultry ovarian health | |
Summers et al. | Feeding Meat Type Pullets and Breeders: 1. Methods for and Significance of Lowering the Live Weight of Meat-Type Pullets at Point of Lay; 2. Evidence on the Protein and Energy Needs of Meat-Type Breeders | |
Hassan | Effect ofinteraction between feed restriction and dietary energy levels on productive, physiological, immunological performance and economic efficiency of two strains of laying hens. | |
El-Mekawy et al. | Effect of certain dietary vitamins supplementation on some productive, reproductive and hatching performance of Japanese quail under Egyptian summer conditions | |
Ali et al. | EFFECT OF FEED RESTRICTION OF JAPANESE QUAIL UNDER NORTH SINAI CONDITIONS. 1-ON GROWTH PERFORMANCE | |
Mahmud et al. | Shafique-ur-Rahman and M |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DSM IP ASSETS B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, SHUEN EI;CHUNG, THAU KIONG;SIGNING DATES FROM 20170721 TO 20170802;REEL/FRAME:044058/0540 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL READY FOR REVIEW |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
STCV | Information on status: appeal procedure |
Free format text: BOARD OF APPEALS DECISION RENDERED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |